EUROAPI Strategically Divests Haverhill Site
EUROAPI has undertaken a significant step in optimizing its industrial footprint by announcing the sale of its Haverhill manufacturing site to Particle Dynamics, a prominent name in particle processing and delivery technologies. This transaction reinforces EUROAPI's commitment to its FOCUS-27 transformation plan aimed at redefining its operational strategies.
Details of the Transaction
The agreement, referred to as the share purchase agreement (SPA), enables Particle Dynamics to acquire 100% of EUROAPI UK Ltd, which oversees the operations at the Haverhill site. The completion of this transaction is expected to bolster Particle Dynamics' ability to offer enhanced solutions in the nutraceutical, consumer health, and pharmaceutical sectors.
EUROAPI's Vision for Future Operations
David Seignolle, the CEO of EUROAPI, highlighted the divestment as a crucial initiative to streamline operations and focus on strategic networks that align with the company’s vision. This strategic move allows EUROAPI to enhance its efficiency while supporting its UK workforce throughout this transition.
Particle Dynamics Takes the Lead
Particle Dynamics sees the acquisition as a vital expansion of their global capabilities in particle engineering. Nicolas Fortin, the company's CEO, emphasized their commitment to upgrading the Haverhill site, including investing in new commercial-scale spray drying technology. This advancement aims to enhance their contract development and manufacturing organization (CDMO) offerings to pharmaceutical innovators.
Financial Terms and Expectations
The financial details of the transaction reveal that it will have a limited impact on EUROAPI's financial statements for the initial half of 2025, as the operations and commitments associated with the site will transfer to Particle Dynamics. Notably, the Haverhill site generated approximately 35 million euros in net sales in a preceding year, with a large portion of that attributed to one significant client. This sale marks a strategic pivot for EUROAPI as it aims to redefine its market presence and operational framework.
About EUROAPI
EUROAPI is committed to innovating active ingredient solutions worldwide, focusing on sustainable practices to meet the diverse needs of its customers and patients. The company stands out as a leading player in the active pharmaceutical ingredient sector, boasting a robust portfolio of around 200 products along with extensive capabilities in research and development.
Commitment to Quality and Access
At the core of EUROAPI’s operations is the drive to ensure health through accessible treatment options. With approximately 3,430 dedicated employees at six manufacturing sites spread across Europe, EUROAPI guarantees the provision of high-quality active pharmaceutical ingredients to clients in over 80 countries.
Key Contacts
Media Relations:
Laurence Bollack
Tel.: +33 (0)6 81 86 80 19
Email: mr@euroapi.com
Investor Relations:
Sophie Palliez-Capian
Tel.: +33 (0)6 87 89 33 51
Email: Sophie.palliez@euroapi.com
Frequently Asked Questions
What is the recent development regarding EUROAPI?
EUROAPI has sold its Haverhill site to Particle Dynamics as part of its operational restructuring.
What is the rationale behind EUROAPI's sale?
The sale is part of a strategic plan to optimize EUROAPI's operations and enhance focus on core capabilities.
How will this impact EUROAPI's financials?
It is anticipated that the sale will have a limited immediate impact on EUROAPI's financial statements for the first half of 2025.
What are the future plans for the Haverhill site?
Particle Dynamics plans to invest in new technologies at the Haverhill site to expand its service offerings to pharmaceutical companies.
What should we know about EUROAPI's market position?
EUROAPI is recognized as a leading player in active pharmaceutical ingredients with a diverse technology portfolio serving clients globally.
